AseBio and the Ministry of Health analyze the challenges and opportunities of Artificial I... 25/06/2024 The event "Challenges and Opportunities for Spain in the Application of AI in Health Data Spaces," organized by AseBio... AseBio
Alira Health Publishes a White Paper on the Impact of New European Union Regulations on Ad... 21/06/2024 Healthcare Access to innovation Drug discovery It provides an overview of the key changes that will impact access to innovative medicines and advanced therapies in the... Partners
ORYZON presents preliminary data from ongoing Phase Ib FRIDA trial with iadademstat plus ... 14/06/2024 Healthcare Access to innovation Drug discovery Rare diseases Data from the first two cohorts demonstrated that combination of iadademstat plus gilteritinib was safe and showed... Partners - Oryzon Genomics
La biotecnología revoluciona la detección temprana del cáncer de próstata, cuya incidencia... 11/06/2024 Salud Acceso a la innovación Digitalización La biotecnología es fundamental en el diagnóstico, tratamiento y seguimiento del cáncer de próstata y desempeña un... AseBio
Biotechnology revolutionizes early detection of prostate cancer, the incidence of which co... 11/06/2024 Biotechnology is central to the diagnosis, treatment and follow-up of prostate cancer and plays a broad role across the... AseBio
Rafael Simó: "We should talk about "obesities" instead of "obesity" because more and more... 06/06/2024 Healthcare Access to innovation Drug discovery Geneis Biomed interviews Dr. Rafael Simón, head of the Endocrinology and Nutrition Department at Vall d'Hebron... Partners - GENESIS Biomed
Use of biotechnology in advanced therapies and new technologies in the spanish market 03/06/2024 Healthcare Access to innovation Advanced therapies Among the most important emerging technologies are the manipulation of the microbiota, CAR-T cell therapies, and gene... Partners - KONEXIO BIOTECH
Oryzon announces journal publication of final Phase IIa ALICE results with iadademstat in ... 03/06/2024 Healthcare Access to innovation Rare diseases Innovative drugs Advanced therapies The Phase IIa study ALICE evaluated the combination of iadademstat plus azacitidine in newly diagnosed, unfit patients... Partners - Oryzon Genomics
Oryzon selected as Associated Partner in the first Important Project of Common European In... 29/05/2024 Healthcare Access to innovation Drug discovery Rare diseases Innovative drugs Personalized medicine Financing Commission has approved up to €1 billion of State aid by six Member States: Belgium, France, Hungary, Italy, Slovakia... Partners - Oryzon Genomics
Collaboration, efficient management of intellectual property and creation of spin-offs, vi... 29/05/2024 Healthcare Access to innovation AseBio has organized, within the framework of the XVII Annual Conference of Biomedical Research Technology Platforms... AseBio
